Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria

blonca9
May 6
1 min read

CEO Klaus Dugi describes why the company is focused on mitochondria and how it using small molecules to fix them. He covers the three main disease areas Vandria is focused on, including a clinical program in mild cognitive impairment.

Recent Posts

See All

Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year

Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight